From Therapy Resistance to Targeted Therapies in Prostate Cancer

Moreira-Silva, Filipa; Henrique, Rui; Jerónimo, Carmen

doi:10.3389/fonc.2022.877379

Cited by 10 publications

(12 citation statements)

References 253 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…( Do and Webster, 2021 ). Unfortunately, the vast majority of PCa patients will develop acquired resistance to most of these therapeutic agents ( Moreira-Silva et al, 2022 ).…”

Section: Discussion and Future Perspectivesmentioning

confidence: 99%

Toad venom-derived bufadienolides and their therapeutic application in prostate cancers: Current status and future directions

Zhou

Han

et al. 2023

Front. Chem.

View full text Add to dashboard Cite

Cancer is the second leading cause of death worldwide. Specially, the high incidence rate and prevalence of drug resistance have rendered prostate cancer (PCa) a great threat to men’s health. Novel modalities with different structures or mechanisms are in urgent need to overcome these two challenges. Traditional Chinese medicine toad venom-derived agents (TVAs) have shown to possess versatile bioactivities in treating certain diseases including PCa. In this work, we attempted to have an overview of bufadienolides, the major bioactive components in TVAs, in the treatment of PCa in the past decade, including their derivatives developed by medicinal chemists to antagonize certain drawbacks of bufadienolides such as innate toxic effect to normal cells. Generally, bufadienolides can effectively induce apoptosis and suppress PCa cells in-vitro and in-vivo, majorly mediated by regulating certain microRNAs/long non-coding RNAs, or by modulating key pro-survival and pro-metastasis players in PCa. Importantly, critical obstacles and challenges using TVAs will be discussed and possible solutions and future perspectives will also be presented in this review. Further in-depth studies are clearly needed to decipher the mechanisms, e.g., targets and pathways, toxic effects and fully reveal their application. The information collected in this work may help evoke more effects in developing bufadienolides as therapeutic agents in PCa.

show abstract

“…( Do and Webster, 2021 ). Unfortunately, the vast majority of PCa patients will develop acquired resistance to most of these therapeutic agents ( Moreira-Silva et al, 2022 ).…”

Section: Discussion and Future Perspectivesmentioning

confidence: 99%

Toad venom-derived bufadienolides and their therapeutic application in prostate cancers: Current status and future directions

Zhou

Han

et al. 2023

Front. Chem.

View full text Add to dashboard Cite

show abstract

“…Among men, prostate cancer is the second most common neoplasm in the world [ 51 , 52 ]. Surgery, radiotherapy, hormone therapy, chemotherapy, and immunotherapy are some of the main treatment modalities, but prostate cancer resistance to conventional therapies remains a significant problem despite the availability of these treatment options [ 77 , 78 , 79 ]. Numerous studies in recent years have revealed ways to improve the effectiveness of antineoplastic therapy, including the incorporation of drugs or natural compounds with multi-functional nanoparticles, aiming to increase the immune system’s ability to identify and attack malignant cells [ 79 , 80 , 81 ].…”

Section: Recent Progress In Niosomes As Delivery Systems In Cancer Th...mentioning

confidence: 99%

Niosomes: Composition, Formulation Techniques, and Recent Progress as Delivery Systems in Cancer Therapy

Liga,

Paul,

Moacă

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Niosomes are vesicular nanocarriers, biodegradable, relatively non-toxic, stable, and inexpensive, that provide an alternative for lipid-solid carriers (e.g., liposomes). Niosomes may resolve issues related to the instability, fast degradation, bioavailability, and insolubility of different drugs or natural compounds. Niosomes can be very efficient potential systems for the specific delivery of anticancer, antioxidant, anti-inflammatory, antimicrobial, and antibacterial molecules. This review aims to present an overview of their composition, the most common formulation techniques, as well as of recent utilizations as delivery systems in cancer therapy.

show abstract

“…Ipatasertib is an Akt inhibitor that has been demonstrated to resensitize CRPC cells to antiandrogens when combined with enzalutamide, inducing apoptosis and leading to remarkable tumor cell growth inhibition, both in vitro and in vivo [ 132 , 133 ].…”

Section: Agents and Strategies To Resensitize Crpc To Antiandrogen Th...mentioning

confidence: 99%

Strategies to Re-Sensitize Castration-Resistant Prostate Cancer to Antiandrogen Therapy

et al. 2023

View full text Add to dashboard Cite

Since prostate cancer (PCa) was described as androgen-dependent, the androgen receptor (AR) has become the mainstay of its systemic treatment: androgen deprivation therapy (ADT). Although, through recent years, more potent drugs have been incorporated, this chronic AR signaling inhibition inevitably led the tumor to an incurable phase of castration resistance. However, in the castration-resistant status, PCa cells remain highly dependent on the AR signaling axis, and proof of it is that many men with castration-resistant prostate cancer (CRPC) still respond to newer-generation AR signaling inhibitors (ARSis). Nevertheless, this response is limited in time, and soon, the tumor develops adaptive mechanisms that make it again nonresponsive to these treatments. For this reason, researchers are focused on searching for new alternatives to control these nonresponsive tumors, such as: (1) drugs with a different mechanism of action, (2) combination therapies to boost synergies, and (3) agents or strategies to resensitize tumors to previously addressed targets. Taking advantage of the wide variety of mechanisms that promote persistent or reactivated AR signaling in CRPC, many drugs explore this last interesting behavior. In this article, we will review those strategies and drugs that are able to resensitize cancer cells to previously used treatments through the use of “hinge” treatments with the objective of obtaining an oncological benefit. Some examples are: bipolar androgen therapy (BAT) and drugs such as indomethacin, niclosamide, lapatinib, panobinostat, clomipramine, metformin, and antisense oligonucleotides. All of them have shown, in addition to an inhibitory effect on PCa, the rewarding ability to overcome acquired resistance to antiandrogenic agents in CRPC, resensitizing the tumor cells to previously used ARSis.

show abstract

From Therapy Resistance to Targeted Therapies in Prostate Cancer

Cited by 10 publications

References 253 publications

Toad venom-derived bufadienolides and their therapeutic application in prostate cancers: Current status and future directions

Toad venom-derived bufadienolides and their therapeutic application in prostate cancers: Current status and future directions

Niosomes: Composition, Formulation Techniques, and Recent Progress as Delivery Systems in Cancer Therapy

Strategies to Re-Sensitize Castration-Resistant Prostate Cancer to Antiandrogen Therapy

Contact Info

Product

Resources

About